Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To determine if physical activity engagement alters the dose-response profile and safety of administration of insulin into the intranasal mucosa.
Using a randomized placebo controlled double-blind pre-posttest design, participants will be randomly assigned to receive a dose of either 0, 20, 40, 60, 80, 100, or 120 IU of NovoLog insulin aspart prior to being randomized into participating in a 20 minute session of either moderate-intensity aerobic exercise or a passive control condition. The efficacy of the intranasal insulin for inducing alterations in cognition will be assessed using both behavioral and neuroelectric measures. The safety of the protocol will be assessed using a symptom questionnaire assessing common symptoms of altered blood glucose and common side effects of intranasal insulin.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Passive Control | Active Comparator | 20 minute sedentary control period during which participants watched an emotionally neutral video. |
|
| Acute Exercise | Experimental | 20 minute physical activity period during which participants exercised on a treadmill at an intensity corresponding to 60-65% of maximum heart rate while watching an emotionally neutral video. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Placebo into the intranasal mucosa | Drug | 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Manifestation of Any Symptom at Any Point During the Protocol | The manifestation of any symptom that could be associated with alterations in blood glucose and side effects of intranasal insulin. Fewer symptoms would indicate a better outcome. Burning/tingling of the nose and watering/tearing of the eyes during the nasal spray were the most cited symptoms. | During the 20 minute exercise/control period and the cognitive assessments. |
| Number of Participants With Manifestation of Any Symptom Following the Protocol | The manifestation of any symptom that could be associated with alterations in blood glucose and side effects of intranasal insulin. Fewer symptoms would indicate a better outcome. The most cited symptom was having a runny nose. | Approximately 1 hour following the dose of intranasal insulin (~32 minutes following the end of the passive control/exercise condition; immediately following the completion of the post-test cognitive assessments) |
| Effect Size for Change in Behavioral Index of Inhibitory Control - RT | The effect size of the change from pre-to-posttest in behavioral metrics of performance (RT) on a flanker test of inhibitory control. A more negative effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis. Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups. | Prior to intranasal insulin administration relative to 30 minutes following |
| Effect Size for Change in Behavioral Index of Inhibitory Control - Accuracy | The effect size of the change from pre-to-posttest in behavioral metrics of performance (response accuracy) on a flanker test of inhibitory control. A more positive effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis. Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups. |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Matthew B Pontifex, Ph.D. | Michigan State University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Kinesiology | East Lansing | Michigan | 48824 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33856613 | Derived | Gwizdala KL, Ferguson DP, Kovan J, Novak V, Pontifex MB. Placebo controlled phase II clinical trial: Safety and efficacy of combining intranasal insulin & acute exercise. Metab Brain Dis. 2021 Aug;36(6):1289-1303. doi: 10.1007/s11011-021-00727-2. Epub 2021 Apr 15. |
Not provided
Not provided
Data sharing will be by request and approval of the Michigan State University Human Research Protections Program with the provision of a data-safety and sharing agreement. No individually identifiable information will be shared.
Data will be available following primary publication of the results.
By request
Not provided
177 individuals were assessed for eligibility. 61 individuals were excluded (58 for failing medical screening, 1 diabetic, 1 unable to exercise, 1 history of epilepsy) 116 individuals were randomized using a serial stratification approach.
Participants were recruited from the mid-Michigan area.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Passive Control - Placebo | 20 minute sedentary control period during which participants watched an emotionally neutral video. Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer |
| FG001 | Passive Control - 20 IU |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Mar 19, 2021 |
Not provided
Not provided
Random allocation to a dose of intranasal insulin (0, 20, 40, 60, 80, 100, 120) Within each dose, random allocation to exercise or control activity.
Not provided
Not provided
Double blind, placebo controlled trial
|
| 20 IU NovoLog Insulin aspart into the intranasal mucosa | Drug | 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
|
|
| 40 IU NovoLog Insulin aspart into the intranasal mucosa | Drug | 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
|
|
| 60 IU NovoLog Insulin aspart into the intranasal mucosa | Drug | 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
|
|
| 80 IU NovoLog Insulin aspart into the intranasal mucosa | Drug | 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
|
|
| 100 IU NovoLog Insulin aspart into the intranasal mucosa | Drug | 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
|
|
| 120 IU NovoLog Insulin aspart into the intranasal mucosa | Drug | 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
|
|
| Prior to intranasal insulin administration relative to 30 minutes following |
| Effect Size of Change in Neuroelectric Index of Attentional Engagement - Inhibition Task | The effect size of the change from pre-to-posttest in neuroelectric measures of attention (P3b amplitude) in response to the flanker test of inhibitory control. The effect size was collapsed across a nine-channel region-of-interest centering around the topographic maxima of the P3 (i.e., the CP3/Z/4, P3/Z/4, PO5/Z/6 electrodes). A larger effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis. Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups. | Prior to intranasal insulin administration relative to 30 minutes following |
| Effect Size of Change in Neuroelectric Index of Attentional Processing Speed - Inhibition Task | The effect size of the change from pre-to-posttest in neuroelectric measures of attention (P3b latency) in response to the flanker test of inhibitory control. The effect size was collapsed across a nine-channel region-of-interest centering around the topographic maxima of the P3 (i.e., the CP3/Z/4, P3/Z/4, PO5/Z/6 electrodes). A smaller effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis. Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups. | Prior to intranasal insulin administration relative to 30 minutes following |
| Effect Size of Change in Behavioral Index of Sustained Attention - RT | The effect size of the change from pre-to-posttest in behavioral metrics of performance (RT) on a Rapid Visual Information Processing test of sustained attention. A more negative effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis. Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups. | Prior to intranasal insulin administration relative to 30 minutes following |
| Effect Size of Change in Behavioral Index of Sustained Attention - Accuracy | The effect size of the change from pre-to-posttest in behavioral metrics of performance (response accuracy) on a Rapid Visual Information Processing test of sustained attention. A more positive effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis. Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups. | Prior to intranasal insulin administration relative to 30 minutes following |
| Effect Size of Change in Neuroelectric Index of Attentional Engagement - RVIP Task | The effect size of the change from pre-to-posttest in neuroelectric measures of attention (P3b amplitude) in response to the target trial of the Rapid Visual Information Processing test of sustained attention. The effect size was collapsed across a nine-channel region-of-interest centering around the topographic maxima of the P3 (i.e., the CP3/Z/4, P3/Z/4, PO5/Z/6 electrodes). A larger effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis. Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups. | Prior to intranasal insulin administration relative to 30 minutes following |
| Effect Size of Change in Neuroelectric Index of Attentional Processing Speed - RVIP Task | The effect size of the change from pre-to-posttest in neuroelectric measures of attention (P3b latency) in response to the target trial of the Rapid Visual Information Processing test of sustained attention. The effect size was collapsed across a nine-channel region-of-interest centering around the topographic maxima of the P3 (i.e., the CP3/Z/4, P3/Z/4, PO5/Z/6 electrodes). A smaller effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis. Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups. | Prior to intranasal insulin administration relative to 30 minutes following |
20 minute sedentary control period during which participants watched an emotionally neutral video. 20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| FG002 | Passive Control - 40 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| FG003 | Passive Control - 60 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| FG004 | Passive Control - 80 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| FG005 | Passive Control - 100 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| FG006 | Passive Control - 120 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| FG007 | Acute Exercise - Placebo | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer |
| FG008 | Acute Exercise - 20 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| FG009 | Acute Exercise - 40 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| FG010 | Acute Exercise - 60 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| FG011 | Acute Exercise - 80 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| FG012 | Acute Exercise - 100 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| FG013 | Acute Exercise - 120 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Passive Control - Placebo | 20 minute sedentary control period during which participants watched an emotionally neutral video. Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer |
| BG001 | Passive Control - 20 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| BG002 | Passive Control - 40 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| BG003 | Passive Control - 60 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| BG004 | Passive Control - 80 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| BG005 | Passive Control - 100 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| BG006 | Passive Control - 120 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| BG007 | Acute Exercise - Placebo | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer |
| BG008 | Acute Exercise - 20 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| BG009 | Acute Exercise - 40 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| BG010 | Acute Exercise - 60 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| BG011 | Acute Exercise - 80 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| BG012 | Acute Exercise - 100 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| BG013 | Acute Exercise - 120 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| BG014 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Race (NIH/OMB) | Count of Participants | Participants |
| ||||||||||||||||
| Region of Enrollment | Count of Participants | Participants |
| ||||||||||||||||
| Education | Mean | Standard Deviation | years |
| |||||||||||||||
| WASI-II (IQ) | Wechsler Abbreviated Scale of Intelligence (2nd Edition) Scores represents performance on the Vocabulary and Matrix Reasoning subtests. For each test the scores are converted to T scores. T scores on each scale are summed together. Scores range from 45 to 160 with higher values representing better performance. | Mean | Standard Deviation | units on a scale |
| ||||||||||||||
| Fasting blood glucose (mg/dL) | Mean | Standard Deviation | mg/dL |
| |||||||||||||||
| Aerobic fitness percentile | Relative peak oxygen consumption (ml/kg/min) was measured using indirect calorimetry during a maximal exercise test and then converted to percentiles based upon normative data taking into account age and biological sex. Percentiles range from 3 to 97 with higher values reflecting a greater aerobic capacity. | Mean | Standard Deviation | percentile |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants With Manifestation of Any Symptom at Any Point During the Protocol | The manifestation of any symptom that could be associated with alterations in blood glucose and side effects of intranasal insulin. Fewer symptoms would indicate a better outcome. Burning/tingling of the nose and watering/tearing of the eyes during the nasal spray were the most cited symptoms. | Posted | Count of Participants | Participants | During the 20 minute exercise/control period and the cognitive assessments. |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Number of Participants With Manifestation of Any Symptom Following the Protocol | The manifestation of any symptom that could be associated with alterations in blood glucose and side effects of intranasal insulin. Fewer symptoms would indicate a better outcome. The most cited symptom was having a runny nose. | Posted | Count of Participants | Participants | Approximately 1 hour following the dose of intranasal insulin (~32 minutes following the end of the passive control/exercise condition; immediately following the completion of the post-test cognitive assessments) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Effect Size for Change in Behavioral Index of Inhibitory Control - RT | The effect size of the change from pre-to-posttest in behavioral metrics of performance (RT) on a flanker test of inhibitory control. A more negative effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis. Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups. | Posted | Mean | 95% Confidence Interval | cohens d | Prior to intranasal insulin administration relative to 30 minutes following |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Effect Size for Change in Behavioral Index of Inhibitory Control - Accuracy | The effect size of the change from pre-to-posttest in behavioral metrics of performance (response accuracy) on a flanker test of inhibitory control. A more positive effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis. Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups. | Posted | Mean | 95% Confidence Interval | cohens d | Prior to intranasal insulin administration relative to 30 minutes following |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Effect Size of Change in Neuroelectric Index of Attentional Engagement - Inhibition Task | The effect size of the change from pre-to-posttest in neuroelectric measures of attention (P3b amplitude) in response to the flanker test of inhibitory control. The effect size was collapsed across a nine-channel region-of-interest centering around the topographic maxima of the P3 (i.e., the CP3/Z/4, P3/Z/4, PO5/Z/6 electrodes). A larger effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis. Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups. | Posted | Mean | 95% Confidence Interval | cohens d | Prior to intranasal insulin administration relative to 30 minutes following |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Effect Size of Change in Neuroelectric Index of Attentional Processing Speed - Inhibition Task | The effect size of the change from pre-to-posttest in neuroelectric measures of attention (P3b latency) in response to the flanker test of inhibitory control. The effect size was collapsed across a nine-channel region-of-interest centering around the topographic maxima of the P3 (i.e., the CP3/Z/4, P3/Z/4, PO5/Z/6 electrodes). A smaller effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis. Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups. | Posted | Mean | 95% Confidence Interval | cohens d | Prior to intranasal insulin administration relative to 30 minutes following |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Effect Size of Change in Behavioral Index of Sustained Attention - RT | The effect size of the change from pre-to-posttest in behavioral metrics of performance (RT) on a Rapid Visual Information Processing test of sustained attention. A more negative effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis. Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups. | Posted | Mean | 95% Confidence Interval | cohens d | Prior to intranasal insulin administration relative to 30 minutes following |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Effect Size of Change in Behavioral Index of Sustained Attention - Accuracy | The effect size of the change from pre-to-posttest in behavioral metrics of performance (response accuracy) on a Rapid Visual Information Processing test of sustained attention. A more positive effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis. Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups. | Posted | Mean | 95% Confidence Interval | cohens d | Prior to intranasal insulin administration relative to 30 minutes following |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Effect Size of Change in Neuroelectric Index of Attentional Engagement - RVIP Task | The effect size of the change from pre-to-posttest in neuroelectric measures of attention (P3b amplitude) in response to the target trial of the Rapid Visual Information Processing test of sustained attention. The effect size was collapsed across a nine-channel region-of-interest centering around the topographic maxima of the P3 (i.e., the CP3/Z/4, P3/Z/4, PO5/Z/6 electrodes). A larger effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis. Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups. | Posted | Mean | 95% Confidence Interval | cohens d | Prior to intranasal insulin administration relative to 30 minutes following |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Effect Size of Change in Neuroelectric Index of Attentional Processing Speed - RVIP Task | The effect size of the change from pre-to-posttest in neuroelectric measures of attention (P3b latency) in response to the target trial of the Rapid Visual Information Processing test of sustained attention. The effect size was collapsed across a nine-channel region-of-interest centering around the topographic maxima of the P3 (i.e., the CP3/Z/4, P3/Z/4, PO5/Z/6 electrodes). A smaller effect size would indicate a better outcome. Effect sizes were computed for each participant as the standardized change relative to the pretest assessment using the within-subject (drm) variance correction for Cohen's d (Lakens, 2013). To ensure the integrity of the effect size estimates, within-subject effect sizes exceeding 3 times the interquartile range were identified as outliers and removed from analysis. Effect sizes are computed per Arm and do not reflect comparisons or combinations across Arms/Groups. | Posted | Mean | 95% Confidence Interval | cohens d | Prior to intranasal insulin administration relative to 30 minutes following |
|
Only during the two 90 minute sessions.
The clinicaltrials.gov definitions for adverse events was used. Indications of onset of an issue related to hypoglycemia were stopping criteria for the study protocol and are considered herein as Non serious adverse events.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Passive Control - Placebo | 20 minute sedentary control period during which participants watched an emotionally neutral video. Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer | 0 | 8 | 0 | 8 | 0 | 8 |
| EG001 | Passive Control - 20 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer | 0 | 8 | 0 | 8 | 0 | 8 |
| EG002 | Passive Control - 40 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer | 0 | 9 | 0 | 9 | 0 | 9 |
| EG003 | Passive Control - 60 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer | 0 | 8 | 0 | 8 | 0 | 8 |
| EG004 | Passive Control - 80 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer | 0 | 8 | 0 | 8 | 0 | 8 |
| EG005 | Passive Control - 100 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer | 0 | 9 | 0 | 9 | 0 | 9 |
| EG006 | Passive Control - 120 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer | 0 | 8 | 0 | 8 | 0 | 8 |
| EG007 | Acute Exercise - Placebo | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer | 0 | 10 | 0 | 10 | 1 | 10 |
| EG008 | Acute Exercise - 20 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer | 0 | 8 | 0 | 8 | 0 | 8 |
| EG009 | Acute Exercise - 40 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer | 0 | 8 | 0 | 8 | 0 | 8 |
| EG010 | Acute Exercise - 60 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer | 0 | 7 | 0 | 7 | 0 | 7 |
| EG011 | Acute Exercise - 80 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer | 0 | 7 | 0 | 7 | 0 | 7 |
| EG012 | Acute Exercise - 100 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer | 0 | 9 | 0 | 9 | 1 | 9 |
| EG013 | Acute Exercise - 120 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer | 0 | 9 | 0 | 9 | 2 | 9 |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Hypoglycemic event | Metabolism and nutrition disorders | Non-systematic Assessment | Blood sugar fell below 70 mg/Dl or exhibited Dizziness |
|
As the present investigation was a Phase II Clinical Trial, the research design was not sufficiently powered for hypothesis testing. Given the potential risk of combining exercise with intranasal insulin the present investigation utilized a sample of healthy, non-diabetic, fasted college-aged adults to limit the potential for a serious adverse event.
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Matthew B. Pontifex | Michigan State University | 517-432-5105 | pontifex@msu.edu |
| Mar 19, 2021 |
| Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D007333 | Insulin Resistance |
| D009043 | Motor Activity |
| ID | Term |
|---|---|
| D006946 | Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D001519 | Behavior |
Not provided
Not provided
| ID | Term |
|---|---|
| D012965 | Sodium Chloride |
| ID | Term |
|---|---|
| D002712 | Chlorides |
| D006851 | Hydrochloric Acid |
| D017606 | Chlorine Compounds |
| D007287 | Inorganic Chemicals |
| D017670 | Sodium Compounds |
Not provided
Not provided
| Male |
|
| Not Hispanic or Latino |
|
| Unknown or Not Reported |
|
| Asian |
|
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|
| OG003 | Passive Control - 60 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG004 | Passive Control - 80 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG005 | Passive Control - 100 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG006 | Passive Control - 120 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG007 | Acute Exercise - Placebo | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG008 | Acute Exercise - 20 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG009 | Acute Exercise - 40 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG010 | Acute Exercise - 60 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG011 | Acute Exercise - 80 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG012 | Acute Exercise - 100 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG013 | Acute Exercise - 120 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
|
|
| OG002 | Passive Control - 40 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG003 | Passive Control - 60 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG004 | Passive Control - 80 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG005 | Passive Control - 100 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG006 | Passive Control - 120 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG007 | Acute Exercise - Placebo | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG008 | Acute Exercise - 20 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG009 | Acute Exercise - 40 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG010 | Acute Exercise - 60 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG011 | Acute Exercise - 80 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG012 | Acute Exercise - 100 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG013 | Acute Exercise - 120 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
|
|
| OG002 | Passive Control - 40 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG003 | Passive Control - 60 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG004 | Passive Control - 80 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG005 | Passive Control - 100 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG006 | Passive Control - 120 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG007 | Acute Exercise - Placebo | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG008 | Acute Exercise - 20 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG009 | Acute Exercise - 40 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG010 | Acute Exercise - 60 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG011 | Acute Exercise - 80 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG012 | Acute Exercise - 100 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG013 | Acute Exercise - 120 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
|
|
| OG002 | Passive Control - 40 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG003 | Passive Control - 60 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG004 | Passive Control - 80 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG005 | Passive Control - 100 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG006 | Passive Control - 120 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG007 | Acute Exercise - Placebo | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG008 | Acute Exercise - 20 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG009 | Acute Exercise - 40 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG010 | Acute Exercise - 60 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG011 | Acute Exercise - 80 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG012 | Acute Exercise - 100 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG013 | Acute Exercise - 120 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
|
|
| OG002 | Passive Control - 40 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG003 | Passive Control - 60 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG004 | Passive Control - 80 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG005 | Passive Control - 100 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG006 | Passive Control - 120 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG007 | Acute Exercise - Placebo | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG008 | Acute Exercise - 20 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG009 | Acute Exercise - 40 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG010 | Acute Exercise - 60 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG011 | Acute Exercise - 80 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG012 | Acute Exercise - 100 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG013 | Acute Exercise - 120 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
|
|
| OG002 | Passive Control - 40 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG003 | Passive Control - 60 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG004 | Passive Control - 80 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG005 | Passive Control - 100 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG006 | Passive Control - 120 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG007 | Acute Exercise - Placebo | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG008 | Acute Exercise - 20 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG009 | Acute Exercise - 40 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG010 | Acute Exercise - 60 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG011 | Acute Exercise - 80 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG012 | Acute Exercise - 100 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG013 | Acute Exercise - 120 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
|
|
| OG002 | Passive Control - 40 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG003 | Passive Control - 60 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG004 | Passive Control - 80 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG005 | Passive Control - 100 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG006 | Passive Control - 120 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG007 | Acute Exercise - Placebo | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG008 | Acute Exercise - 20 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG009 | Acute Exercise - 40 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG010 | Acute Exercise - 60 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG011 | Acute Exercise - 80 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG012 | Acute Exercise - 100 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG013 | Acute Exercise - 120 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
|
|
| OG002 | Passive Control - 40 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG003 | Passive Control - 60 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG004 | Passive Control - 80 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG005 | Passive Control - 100 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG006 | Passive Control - 120 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG007 | Acute Exercise - Placebo | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG008 | Acute Exercise - 20 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG009 | Acute Exercise - 40 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG010 | Acute Exercise - 60 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG011 | Acute Exercise - 80 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG012 | Acute Exercise - 100 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG013 | Acute Exercise - 120 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
|
|
| OG002 | Passive Control - 40 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG003 | Passive Control - 60 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG004 | Passive Control - 80 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG005 | Passive Control - 100 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG006 | Passive Control - 120 IU | 20 minute sedentary control period during which participants watched an emotionally neutral video. 120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG007 | Acute Exercise - Placebo | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. Placebo into the intranasal mucosa: 6 doses of 0.2mL saline solution administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG008 | Acute Exercise - 20 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 20 IU NovoLog Insulin aspart into the intranasal mucosa: 5 doses of 0.2mL saline solution, 1 dose of 0.2mL NovoLog Insulin aspart (20 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG009 | Acute Exercise - 40 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 40 IU NovoLog Insulin aspart into the intranasal mucosa: 4 doses of 0.2mL saline solution, 2 doses of 0.2mL NovoLog Insulin aspart (40 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG010 | Acute Exercise - 60 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 60 IU NovoLog Insulin aspart into the intranasal mucosa: 3 doses of 0.2mL saline solution, 3 doses of 0.2mL NovoLog Insulin aspart (60 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG011 | Acute Exercise - 80 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 80 IU NovoLog Insulin aspart into the intranasal mucosa: 2 doses of 0.2mL saline solution, 4 doses of 0.2mL NovoLog Insulin aspart (80 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG012 | Acute Exercise - 100 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 100 IU NovoLog Insulin aspart into the intranasal mucosa: 1 dose of 0.2mL saline solution, 5 doses of 0.2mL NovoLog Insulin aspart (100 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
| OG013 | Acute Exercise - 120 IU | 20 minute physical activity period during which participants exercised on a treadmill at 60-65% of maximum heart rate. 120 IU NovoLog Insulin aspart into the intranasal mucosa: 6 doses of 0.2mL NovoLog Insulin aspart (120 IU) administered into the intranasal mucosa using the MAD Nasal Atomizer |
|
|